Unichem Labs Stock: Profit ka **357%** jump, par asli business mein **30%** girawat! Land sale ne kiya kamaal?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Unichem Labs Stock: Profit ka **357%** jump, par asli business mein **30%** girawat! Land sale ne kiya kamaal?
Overview

Unichem Labs ke investors, aaj ek zabardast number dikh raha hai! Company ka consolidated PAT **357%** se zyada bhag gaya, pohoch gaya **₹264.29 crore** par. Ye sab hua ek land aur building ki sale se, jisme **₹275.52 crore** ka faayda hua. Par asli khel toh standalone revenue mein hai, jo **29.69%** gir kar **₹314.90 crore** ho gaya!

Toh bhai, Unichem Labs ke Q3 FY26 results aa gaye hain aur numbers thoda confusing hain. Company ka consolidated PAT toh 356.86% toofan ki speed se bhaga hai, ₹264.29 crore tak pahunch gaya hai last year ke ₹57.85 crore se. Yeh bhagdaad asal mein ek land aur building ki sale ki wajah se hai, jisse company ko ₹275.52 crore ka fayda hua.

Standalone Business Ka Kya Scene Hai?

Lekin ruk jao! Yeh jo PAT mein bada jump dikh raha hai, woh asli business ki performance nahi hai. Company ka standalone revenue toh 29.69% se gir gaya hai, pohoch gaya hai ₹314.90 crore par. Haalanki, standalone PAT bhi 360.86% badh kar ₹216.11 crore ho gaya, but yeh bhi ussi ₹275.52 crore ke land sale gain ki wajah se hai. Iska matlab asli operations mein dabav hai. Standalone EPS bhi ₹30.69 ho gaya, jo pehle ₹6.66 tha.

9 Mahine Ka Report Card

Agar 9 mahine ki baat karein, toh consolidated revenue 6.76% badh kar ₹1,626.73 crore hua, aur consolidated PAT 186.14% badh kar ₹241.93 crore ho gaya. Lekin isme bhi ₹217.26 crore ke exceptional items shamil hain, jisme land sale gain aur ek European Commission fine par interest bhi tha. Wahi, standalone revenue 17.14% gir kar ₹1,056.05 crore raha.

Asli Chinta Aur Risks

Sabse badi chinta ye hai ki standalone revenue 29.69% kam ho gaya hai, jo dikhata hai ki company ke core business mein issues chal rahe hain. Profit mein jo jump hai woh ek baar ki asset sale se hai, asli operational health isse nahi pata chalti. Plus, company ne koi future guidance ya outlook nahi diya hai, toh investors ko pata hi nahi chalega ki aage kya hone wala hai. Auditor ne bhi kuch subsidiaries ke figures par sawal uthaye hain.

Governance Update

Ek achhi khabar yeh hai ki Dr. (Ms.) Swati Patankar ko as a Non-Executive Independent Director appoint kiya gaya hai. Lekin, jab tak management clarity nahi deta aur revenue girne ki wajah nahi batata, tab tak investors ko headline numbers ke peeche dekhna padega.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.